Biotech RadarJobs updated

COMPANY

XBiotech

HQ: Austin, TX source · xbiotech.com ↗

Clinical Phase 2

Keywords: antibody infectious disease oncology infectious diseases arthritis cancer Rheumatoid Arthritis Pancreatic Cancer Axial Spondyloarthritis Ankylosing Spondylitis r-axSpA Nr-axSpA Staphylococcus Aureus Bacteremia Natrunix vilamakitug

Location: Austin, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

8Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy source ↗
  2. Trial start Phase 2: Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment source ↗
  3. Trial start Phase 2: Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis source ↗
  4. Trial start Phase 1: Hutrukin to Analyze Safety and PK in Healthy Volunteers source ↗
  5. Trial start Phase 2: Natrunix Versus Methotrexate in Rheumatoid Arthritis source ↗
  6. Trial start Phase 1: Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers source ↗
  7. Trial start Phase 1/Phase 2: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer source ↗
  8. Trial start Phase 1/Phase 2: Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects. source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 8

RecordTitlePhaseStatusStartPrimary completion
NCT05099510Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy VolunteersPhase 1CompletedJan 19, 2022Aug 8, 2022 (actual)
NCT04825288XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic CancerPhase 1/Phase 2CompletedMay 27, 2021Oct 26, 2023 (actual)
NCT06526377Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for EfficacyPhase 2Not yet recruiting2026-092028-09 (estimated)
NCT02357966Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.Phase 1/Phase 2Completed2015-052016-12 (actual)
NCT06590090Natrunix in Combination With Methotrexate for Rheumatoid Arthritis TreatmentPhase 2Not yet recruitingJul 15, 2026Jan 15, 2027 (estimated)
NCT05363891Natrunix or Placebo in Combination With Methotrexate in Rheumatoid ArthritisPhase 2CompletedAug 8, 2023Oct 31, 2024 (actual)
NCT05098080Hutrukin to Analyze Safety and PK in Healthy VolunteersPhase 1CompletedApr 10, 2023Oct 24, 2023 (actual)
NCT05363917Natrunix Versus Methotrexate in Rheumatoid ArthritisPhase 2Unknown status (ClinicalTrials.gov)Jun 15, 2022Dec 15, 2022 (estimated)
Feedback